Mortality After Piperacillin-Tazobactam-Resistant vs -Susceptible Bloodstream Infection.
Similar mortality rates for piperacillin-tazobactam-resistant vs -susceptible E. coli bloodstream infections.
Mortality After Piperacillin-Tazobactam-Resistant vs -Susceptible Bloodstream Infection.
IMPORTANCE: Use of piperacillin-tazobactam (TZP) as treatment for bloodstream infections (bloodstream infections) has increased over time in Europe, as has antimicrobial resistance to TZP in some European countries.
To evaluate mortality associated with TZP-resistant bloodstream infections in the Danish health care system.
DESIGN, SETTING, AND PARTICIPANTS: In this cohort study, data collected in near real time were obtained from Danish national health registers from November 15, 2018, through November 21, 2024.
similar risk of death for E. coli blood infections resistant vs susceptible to antibiotic
The study population included 34 379 patients (median overall age, 76 years [IQR, 66-83 years]; 51.5% male).
Among 28 649 patients (81.9%) with E coli bloodstream infections, 1689 (5.9%) had a TZP-resistant bloodstream infections; among 6314 patients (18.1%) with K pneumoniae bloodstream infections, 597 (9.5%) had a TZP-resistant bloodstream infections.
There was no loss to follow-up, and about 1% of participants were right-censored by the end of the observation period (E coli: 343 [1.2%]; K pneumoniae, 88 [1.4%]).
In this cohort study of patients with monomicrobial E coli or K pneumoniae bloodstream infections, there was no significant difference in mortality for patients with bloodstream infections caused by TZP-resistant vs TZP-susceptible bacteria after adjustment for baseline risk factors.
The result is important given increasing TZP resistance in Denmark and other countries.